
Erlotinib Tablets
| Product/Composition | Erlotinib Tablets |
|---|---|
| Strength | 100mg, 150 Mg |
| Form | Tablets |
| Production Capacity | 10 Million Tablets/Month |
| Packaging | 1 X 30 Tablets / Bottle |
| Therapeutic use | Anti Cancer |
| Package Insert/Leaflet | Available upon request |
Erlotinib Tablets are a medicine used in the treatment of certain types of cancer, specifically targeting abnormal cell growth. They belong to a class of drugs called tyrosine kinase inhibitors (TKIs).
Here are the key details:
-
Composition: Each tablet contains Erlotinib hydrochloride as the active ingredient, commonly in strengths like 25 mg, 100 mg, and 150 mg.
-
Dosage Form: Oral tablets, usually taken once daily, on an empty stomach or as directed by a doctor.
-
Mode of Action:
-
Erlotinib inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in the growth and spread of cancer cells.
-
By blocking EGFR, it slows cancer cell growth and can induce cancer cell death.
-
-
Uses:
-
Non-small cell lung cancer (NSCLC) – particularly in patients with EGFR mutations.
-
Pancreatic cancer – in combination with other chemotherapeutic agents.
-
-
Treatment Goal: To slow cancer progression, reduce tumor size, and improve survival in patients with EGFR-positive cancers.
-
Side Effects:
-
Common: rash, diarrhea, loss of appetite, fatigue, nausea, vomiting.
-
Less common/serious: liver problems, interstitial lung disease, severe skin reactions, eye irritation.
-
-
Precautions:
-
Regular monitoring of liver function and skin condition is recommended.
-
Avoid taking with strong acid-reducing medications unless advised by a doctor, as they may reduce absorption.
-
Not recommended during pregnancy or breastfeeding.
-
Can interact with certain medications that affect liver enzymes, altering drug levels.
-
👉 Erlotinib is a targeted cancer therapy, specifically effective for cancers driven by EGFR mutations, providing a more precise approach than traditional chemotherapy.